Comar has authorised child-resistant (CR) packaging for its SecureCap closures, which is set by Consumer Product Safety Commission (CPSC).
The SecureCap package has underwent United States Pharmacopeia testing for extractables and light transmission, container performance testing for moisture vapor transmission rates (MVTR) and CPSC protocol of the Code of Federal Regulations (CFR) for child-resistant package testing.
Currently, Comar is providing 15 millimeter SecureCap closures that can be used for eye drops and nasal sprays containing 0.08mg and imidazolines.
SecureCap closures, which feature two-piece push and Comar's patented turn technology, are available in custom sizes and configurations.
Comar president and CEO Mike Ruggieri said that for some OTC and prescription manufacturers, compliance with the CPSC requirement for CR packaging may result in delays and costly retooling of filling processes to accommodate new closures.
"Our SecureCap closures are a stocked item, and we are working closely with our customers to assist them in complying with the CPSC regulation as quickly as possible," Ruggieri added.
